2008-11-21 22:23:04 -
Depomed, Inc. (NASDAQ:DEPO), a specialty pharmaceutical company with a proven, proprietary technology, AcuForm, announced today that it will be hosting a conference call on Monday, November 24, 2008 at 4:30 PM EST. The purpose of the call is to discuss the product license agreement under which Solvay Pharmaceuticals will have exclusive rights for DM-1796 (formerly Gabapentin GR®) for the treatment
of pain in the United States, Canada, Mexico and Puerto Rico and to provide an update on Depomed"s business.
The conference call will be available via a live webcast on the investor relations section of Depomed"s website at
cts.businesswire.com/ct/CT"id=smartlink&url=http%3A%2F%2Fwww ... Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company"s website for three months.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market and other product candidates in its pipeline. The company utilizes its proven, proprietary AcuFormTM drug delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of AcuForm-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. GLUMETZA® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Proquin® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is being marketed in the United States within the urology, Ob/Gyn and long-term care specialties by Watson Pharmaceuticals. Product candidate DM-1796 is in clinical development for the treatment of neuropathic pain and has been licensed to Solvay Pharmaceuticals. Product candidate DM-5689 is in clinical development for menopausal hot flashes. Additional information about Depomed may be found on its website,
cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww ...
Depomed, Inc.
Sheilah Serradell, 650-462-5900
mailto:investorrelations@depomed.com
